Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

Key Takeaways from the Antibody-drug Conjugates Competitive Landscape Report Key Takeaways from the Antibody-drug Conjugates Competitive Landscape Report Request a sample and discover the recent advances in antibody-drug conjugates treatment @Antibody-drug Conjugates Competitive Landscape Report Antibody-drug Conjugates Overview Antibody-drug conjugates (ADC) are one of the most rapidly increasing anticancer treatments. This method uses a mAb attached to a lethal payload via...

Key Takeaways from the Antibody-drug Conjugates Competitive Landscape Report

Request a sample and discover the recent advances in antibody-drug conjugates treatment @ Antibody-drug Conjugates Competitive Landscape Report

Antibody-drug Conjugates Overview

Antibody-drug conjugates (ADC) are one of the most rapidly increasing anticancer treatments. This method uses a mAb attached to a lethal payload via a chemical linker that is directed towards a target antigen expressed on the cancer cell surface, limiting systemic exposure and thereby toxicity. ADCs are complicated compounds that necessitate close attention to various components. The choice of an acceptable target, a mAb, cytotoxic payload, and the manner in which the antibody is coupled to the payload are all important factors of ADC safety and efficacy. Antibody-drug conjugate (ADC) is a newly emerging family of highly effective pharmacological medications that combine chemotherapy and immunotherapy.

The most commonly targeted antigens in ADCs are ERBB2, CD19, CD33, CD22, and MSLN (mesothelin). Furthermore, over 50 distinct recognized antigens have been employed as targets in ADC. Previous research has shown that several tumor antigens are also expressed at low levels in normal cells. The concept of ADCs is to deliver a highly effective payload to its target utilizing the best carrier possible. ADCs are administered intravenously into the circulation to avoid mAb breakdown by stomach acid and proteolytic enzymes. Ideally, the target antigens must be expressed only on tumor cells and not on normal cells in order for the mAb component of ADCs to detect and bind to them.

Find out more about antibody-drug conjugates drugs @ Antibody-drug Conjugates Treatment

Antibody-drug Conjugates Pipeline Analysis: Drug Profile

Zynlonta: ADC Therapeutics

Zynlonta (loncastuximab tesirine) is a pharmacological combination of a CD19-directed antibody. Zynlonta is internalized by the cell after binding to a CD19-expressing cell, where enzymes release a pyrrolobenzodiazepine payload. The powerful payload binds to the minor groove of DNA with minimal distortion, making it less detectable in DNA repair processes. This eventually leads to cell cycle arrest and cancer cell death. Zynlonta (loncastuximab tesirine-lpyl) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. 

Ladiratuzumab Vedotin: Seagen Inc.

Ladiratuzumab vedotin is an investigational ADC that targets LIV-1. Most metastatic breast tumors express LIV-1, which has also been found in lung, head & neck, esophageal, and gastric malignancies. Ladiratuzumab vedotin is made up of a LIV-1-targeted monoclonal antibody connected to a strong microtubule-disrupting drug, monomethyl auristatin E (MMAE), by a protease-cleavable linker. This unique ADC is intended to bind to LIV-1 on cancer cells and, following internalization, release the cell-killing chemical into target cells. Ladiratuzumab vedotin may also exert anticancer action via other pathways, such as the generation of an immunological response by immunogenic cell death. The drug is currently in Phase II clinical trial evaluation for the treatment of unresectable locally advanced or metastatic solid tumors.

A snapshot of the Antibody-drug Conjugates Pipeline Drugs mentioned in the report:

Learn more about the emerging antibody-drug conjugates pipeline drugs @ Antibody-drug Conjugates Clinical Trials

Scope of the Antibody-drug Conjugates Competitive Landscape Report 

Dive deep into rich insights for new antibody-drug conjugates drugs, visit @ Antibody-drug Conjugates Drugs

Table of Contents

For further information on the antibody-drug conjugates pipeline therapeutics, reach out @ Antibody-drug Conjugates Analysis

Related Reports

Antibody-drug Conjugates Market

Antibody-drug Conjugates Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key antibody-drug conjugates companies, including ImmunoGen, Daiichi Sankyo, AstraZeneca, Seagen, Sorrento Therapeutics, Inc., Mythic Therapeutics, Merck KGaA, NBE-Therapeutics AG, Gilead Sciences, Regeneron Pharmaceuticals, Kirilys Therapeutics Inc., Tanabe Research Laboratories USA Inc, Sutro Biopharma, Inc, among others.

Antibody-drug Conjugates in Oncology Competitive Landscape

Antibody-drug Conjugates in Oncology Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key antibody-drug conjugates in oncology companies, including Seagen, Daiichi Sankyo, AstraZeneca, ADC Therapeutics, Abbvie, Gilead Sciences, Byondis, ImmunoGen, Merck, CytomX, Genmab, MacroGenics, among others.

Bispecific Antibody Competitive Landscape

Bispecific Antibody Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bispecific antibody companies, including Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, among others.

Monoclonal Antibodies Competitive Landscape

Monoclonal Antibodies Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key monoclonal antibody companies, including Novartis, Gmax Biopharm, Omeros Corporation, Merck Sharp & Dohme, Disc Medicine, Eledon Pharmaceuticals, Alexion AstraZeneca Rare Disease, Chinook Therapeutics, Omeros Corporation, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Contact Us
Shruti Thakur  
info@delveinsight.com  
+1(919)321-6187 
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862786.html